Tejnaksh Healthcare Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

Quality Assessment: Weak Fundamentals Persist

Despite the upgrade, Tejnaksh Healthcare’s quality metrics remain underwhelming. The company has exhibited flat financial performance in the third quarter of FY25-26, with no significant growth in operating profits. Over the past five years, operating profits have declined at a compounded annual growth rate (CAGR) of -5.68%, underscoring persistent operational challenges. Return on Equity (ROE) averaged 9.52%, indicating low profitability relative to shareholders’ funds. This figure is below industry averages, reflecting inefficiencies in capital utilisation.

Further, the company’s debtor turnover ratio for the half-year period stands at a low 4.87 times, signalling potential issues in receivables management and cash flow conversion. These factors collectively contribute to a weak fundamental profile, which continues to weigh on investor sentiment.

Valuation: Attractive but Risky

On the valuation front, Tejnaksh Healthcare presents a paradox. The stock trades at a price-to-book (P/B) ratio of 1, which is considered very attractive relative to its peers in the healthcare services sector. This discount to historical valuations suggests potential value for investors willing to tolerate the company’s risks. The current market price of ₹13.66 is closer to its 52-week low of ₹12.10 than the high of ₹24.77, reinforcing the discounted valuation narrative.

However, this valuation attractiveness is tempered by the company’s poor recent returns and profit declines. Over the past year, the stock has generated a negative return of -39.26%, while profits have fallen by -41.2%. Such steep declines highlight the risks embedded in the stock despite its low valuation multiples.

Financial Trend: Flat to Negative Performance

Tejnaksh Healthcare’s financial trend remains largely flat to negative. The company’s quarterly results for December 2025 showed no meaningful growth, reflecting stagnation in core operations. Over the last one year, the stock’s return of -39.26% starkly contrasts with the Sensex’s modest decline of -1.67%, indicating significant underperformance against the broader market.

Longer-term trends are even more concerning. Over three and five years, the stock has lost 63.34% and 62.58% respectively, while the Sensex has gained 23.86% and 50.62% over the same periods. This consistent underperformance against benchmarks and sector peers highlights structural issues in the company’s growth trajectory and market positioning.

Technical Analysis: Signs of Stabilisation Spur Upgrade

The primary driver behind the upgrade from Strong Sell to Sell is an improvement in technical indicators. The technical trend has shifted from bearish to mildly bearish, signalling a tentative stabilisation in the stock’s price momentum. Key technical metrics reveal a mixed but cautiously optimistic picture:

• MACD: Weekly readings have turned mildly bullish, although monthly signals remain bearish, indicating short-term momentum improvement but longer-term caution.
• RSI: Both weekly and monthly Relative Strength Index readings show no clear signal, suggesting the stock is neither overbought nor oversold at present.
• Bollinger Bands: Weekly and monthly bands remain mildly bearish, reflecting ongoing volatility and downward pressure.
• Moving Averages: Daily moving averages continue to be bearish, indicating that the stock price remains below key average price levels.
• KST (Know Sure Thing): Weekly KST is mildly bullish, while monthly remains bearish, reinforcing the mixed technical outlook.
• Dow Theory: Weekly signals are mildly bullish, but no clear monthly trend is established.

These technical nuances suggest that while the stock is not out of the woods, there is a nascent improvement in price action that justifies a less severe rating. The stock’s recent price rise to ₹13.66 from the previous close of ₹12.78, with intraday highs touching ₹13.90, supports this view.

Comparative Returns: Underperformance Persists

Despite the technical upgrade, Tejnaksh Healthcare’s returns continue to lag significantly behind the Sensex and sector benchmarks. Over the last week, the stock outperformed with a 14.50% gain versus the Sensex’s 3.00%, and over the last month, it posted a modest 2.86% gain compared to the Sensex’s -6.10%. However, year-to-date returns remain negative at -8.87%, trailing the Sensex’s -13.04% decline.

Longer-term returns paint a bleaker picture. The stock’s 10-year return of 222.24% slightly outpaces the Sensex’s 197.61%, but this is overshadowed by severe underperformance over the last three and five years. This inconsistency highlights the stock’s volatility and the challenges investors face in timing entry and exit points.

Ownership and Market Capitalisation

Tejnaksh Healthcare remains a micro-cap stock with a market capitalisation grade reflecting its relatively small size in the healthcare services sector. The majority shareholding is held by promoters, which can be a double-edged sword—providing stability but also raising concerns about liquidity and governance for some investors.

Conclusion: Cautious Optimism Amidst Structural Challenges

The upgrade of Tejnaksh Healthcare Ltd’s investment rating from Strong Sell to Sell by MarketsMOJO on 6 April 2026 is primarily driven by technical improvements signalling a potential bottoming out of the stock price. However, fundamental weaknesses remain pronounced, with flat financial performance, weak profitability metrics, and consistent underperformance against benchmarks over multiple time horizons.

Valuation metrics offer some appeal, with the stock trading at a discount to peers and a low price-to-book ratio, but this is counterbalanced by significant profit declines and operational challenges. Investors should weigh the improved technical outlook against the company’s structural issues and consider the stock’s volatility and micro-cap status before making investment decisions.

Overall, the rating change reflects a nuanced view that acknowledges short-term technical stabilisation without overlooking the longer-term fundamental headwinds facing Tejnaksh Healthcare Ltd.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today